Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/15/24
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerGlobeNewsWire • 04/29/24
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024GlobeNewsWire • 04/24/24
Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementGlobeNewsWire • 04/16/24
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/14/24
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 03/01/24
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/18/23
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 CytokinesGlobeNewsWire • 12/14/23
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/08/23
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023GlobeNewsWire • 11/03/23
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/10/23
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaGlobeNewsWire • 08/09/23
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion MutationsPRNewsWire • 08/03/23
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023GlobeNewsWire • 05/25/23
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/11/23
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023GlobeNewsWire • 04/26/23
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 CytokinesGlobeNewsWire • 03/27/23
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual MeetingGlobeNewsWire • 03/14/23
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/09/23